Fennec Pharmaceuticals (TSX:FRX) ROCE %: 1.36% (As of Mar. 2026)


TSX:FRX Fennec Pharmaceuticals Inc TSX:FRX
53 GF Score
Price C$15.24
GF Value C$14.13
Valuation Fairly Valued
! 2 Warning Signs
View Full Analysis

What is Fennec Pharmaceuticals ROCE %?

Fennec Pharmaceuticals TSX:FRX +1.60% 53 ROCE % is 1.36% as of Mar. 2026. GuruFocus rates TSX:FRX with a GF Score™ of 53/100 and a GF Value™ of C$14.13 (Fairly Valued). The stock has 2 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Fennec Pharmaceuticals's annualized ROCE % for the quarter that ended in Mar. 2026 was 1.36%.

Fennec Pharmaceuticals  (TSX:FRX) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Fennec Pharmaceuticals ROCE % Related Terms

Fennec Pharmaceuticals ROCE % Historical Data

* Premium members only.

The historical data trend for Fennec Pharmaceuticals's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Fennec Pharmaceuticals ROCE % Chart

Fennec Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -69.09 -108.55 -60.35 14.22 -15.22

Fennec Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -6.05 -26.78 -0.55 -35.13 1.36
TSX:FRX
53GF Score
Fennec Pharmaceuticals Inc TSX:FRX
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Fennec Pharmaceuticals ROCE % Calculation

Fennec Pharmaceuticals's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=-10.422/( ( (64.035 - 9.857) + (97.325 - 14.51) )/ 2 )
=-10.422/( (54.178+82.815)/ 2 )
=-10.422/68.4965
=-15.22 %

Fennec Pharmaceuticals's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=1.14/( ( (97.325 - 14.51) + (98.54 - 13.152) )/ 2 )
=1.14/( ( 82.815 + 85.388 )/ 2 )
=1.14/84.1015
=1.36 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of 1.36% mean?
Fennec Pharmaceuticals (TSX:FRX) has a ROCE % of 1.36% as of Mar. 2026.
Is Fennec Pharmaceuticals' ROCE % too high?
Fennec Pharmaceuticals' current ROCE % is 1.36%. Overall, Fennec Pharmaceuticals has a GF Score™ of 53/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Fennec Pharmaceuticals' ROCE % compare to VRTX and REGN?
Fennec Pharmaceuticals' ROCE % of 1.36% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Biotechnology company?
A good ROCE % depends on the Biotechnology industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. Fennec Pharmaceuticals's current ROCE % is 1.36%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Fennec Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Fennec Pharmaceuticals (TSX:FRX) is currently considered Fairly Valued. The stock's GF Value™ is C$14.13, compared to a current price of C$15.24 — trading 7.9% above its estimated fair value. The current ROCE % is 1.36%. Fennec Pharmaceuticals' overall GF Score™ is 53/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Fennec Pharmaceuticals (TSX:FRX), the current ROCE % is 1.36% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Fennec Pharmaceuticals (TSX:FRX) Overvalued in 2026?

Based on GuruFocus' analysis, Fennec Pharmaceuticals stock appears to be overvalued. The current stock price of C$15.24 is trading 7.9% above its estimated GF Value™ of C$14.13. GuruFocus considers Fennec Pharmaceuticals to be Fairly Valued.

Key valuation signals for TSX:FRX:

  • ROCE %: 1.36%
  • GF Value™: C$14.13 vs. price of C$15.24 (7.9% above fair value)
  • GF Score™: 53/100 with 2 warning signs

No single metric tells the full story. See the TSX:FRX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Fennec Pharmaceuticals Business Description

Other Exchanges FENC:USARV41:Germany
Address 68 TW Alexander Drive, PO Box 13628, Research Triangle Park, NC, USA, 27709
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.
53GF Score

Get the complete analysis for TSX:FRX

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

C$15.24
Price
C$14.13
GF Value